Sign in Subscribe
Class action lawsuits

Novo Nordisk A/S Securities Lawsuit Alert: Lead Plaintiff Deadline Approaching

Strategic Insights

— 2 min read

Investors who suffered losses in Novo Nordisk A/S (NYSE: NVO) shares between May 7, 2025, and July 28, 2025, may be eligible for a potential recovery under the federal securities laws. A class action securities lawsuit was filed against Novo Nordisk A/S, alleging that the company provided false and misleading statements about its growth potential. This lawsuit seeks to recover losses of shareholders who were affected by the alleged securities fraud. Novo Nordisk A/S announced a significant decline in sales and profit outlook on July 29, 2025, leading to a sharp drop in its stock price.

Key Takeaways:

  • A class action securities lawsuit was filed against Novo Nordisk A/S, alleging securities fraud between May 7, 2025, and July 28, 2025.
  • The lawsuit claims that Novo Nordisk A/S provided false and misleading statements about its growth potential, understating the impact of the personalization exception to the compounded GLP-1 exclusion and overstating the likelihood of patients switching to the company's branded alternatives.
  • The lawsuit alleges that Novo Nordisk A/S concealed material adverse facts about its growth potential and the true state of its business.
  • The price of Novo's common stock declined dramatically after the company announced a lowered sales and profit outlook on July 29, 2025, with a drop of about 21.83% in a single day.
  • The lawsuit seeks to recover losses of shareholders who were affected by the alleged securities fraud.
  • Novo Nordisk A/S attributed the guide down on "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition."
  • The law firm Levi & Korsinsky LLP has expertise in representing investors in complex securities litigation and has secured hundreds of millions of dollars for aggrieved shareholders.

Statistics:

  • The price of Novo's common stock declined from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, a decline of about 21.83% in a single day.
  • The lawsuit seeks to recover losses of shareholders who suffered losses between May 7, 2025, and July 28, 2025.
  • Novo Nordisk A/S has a market capitalization of over $200 billion.
  • The lawsuit was filed in the Southern District of New York.

Sources:

  • [https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=169003&wire=5&utm_campaign=2]
  • [https://www.newsfilecorp.com/release/267440]
  • [Levi & Korsinsky, LLP website: https://zlk.com/]
  • [Newsfile Corp. website: https://www.newsfilecorp.com/]

Read more